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Summary We have used polymerase chain reaction (PCR) analysis to study the incidence of allelic imbalance at four polymorphic
microsatellite markers on chromosome 6q25.1-27, three dinucleotide repeats and one trinucleotide repeat, for microdissected tumour foci
from a group of 75 'early' breast carcinomas. The tumours comprised 16 preinvasive cases of ductal carcinoma in situ (DCIS) and 59
mammographically detected early invasive carcinomas. Loss of heterozygosity (LOH) was detected at all four loci and in all types and grade
of disease. The frequency of LOH ranged from 23% to 50% depending on the marker studied. The highest frequency of LOH was observed
at the D6S186 locus for the cases of DCIS and at the oestrogen receptor locus for the invasive carcinomas. These data suggest that the
inactivation of tumour-suppressor genes within this region on chromosome 6q is important for the development of these early lesions.
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According to the multistep model ofcarcinogenesis, tumours may
develop and progress as a result of alterations in oncogene and
tumour-suppressor gene loci. In colon cancer, a benign to malig-
nant progression with recognizable molecular changes has been
described (Fearon and Volgelstein, 1990). However, the situation
for breast cancer is less clear, since there is no clear understanding
ofthe natural history ofthe disease.
Cytogenetic analyses ofprimary breast tumours have identified
frequent alterations to a number of chromosomes, notably dele-
tions, suggesting the potential localization of tumour-suppressor
genes (for a review, see Devilee and Cornelisse, 1994). These
studies demonstrated that deletion of chromosome 6q was one of
the most frequent chromosomal changes (Dutrillaux et al, 1990;
Mars and Saunders, 1990). A subsequent study, using Southern
analysis ofrestriction fragment length polymorphisms to compare
constitutional and tumour DNAs, identified chromosome 6q as the
second most frequent site for allelic loss (loss of heterozygosity)
after 17p in breast cancer (Deville et al, 1991).
Other evidence for the presence of putative tumour-suppressor
genes on chromosome 6q comes from chromosome-mediated
transfer experiments ofnormal chromosome 6 into melanoma cell
lines (Trent et al, 1990), uterine endometrial cell lines (Yamada
et al, 1990) and the breast cancer cell lines, MDA-MD231 and
MCF-7 (Negrini et al, 1994), all resulting in the suppression of
tumorigenesis.
The advent of polymerase chain reaction (PCR) analysis of
microsatellite polymorphisms (Weber and May, 1989) has
confirmed the cytogenetic evidence for chromosomal deletion at
6q and has enabled construction of a more detailed deletion map.
Allelic loss at 6q24-27 has been observed in different tumour
types, including breast carcinoma (Orphanos et al, 1995), ovarian
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carcinoma (Saito et al, 1992; Rodabaugh et al, 1995), hepatic
carcinoma (De Souza et al, 1995), small-cell lung carcinoma
(Merlo et al, 1994), renal cell carcinoma (Morita et al, 1991),
malignant melanoma (Millikin et al, 1991; Walker et al, 1994) and
non-Hodgkin's lymphoma (Menasce et al, 1994). The reported
frequencies of allelic loss range from 30% to 60% depending on
the tumour types and markers studied. This shared region ofallelic
loss may harbour putative tumour-suppressor genes that are
pleiotropic for these tumour types and reflect a common mecha-
nism oftumorigenesis.
Recent detailed analyses of microsatellite markers on chromo-
some 6q in breast cancers have highlighted two key regions
showing high levels of LOH at 6q13 and 6q26-27, indicating the
presence of at least two tumour-suppressor genes (Devilee et al,
1991; Orphanos et al, 1995). Since these studies were concerned
with symptomatic, well-established breast carcinomas, it is not
clear whether allelic loss on chromosome 6q is an early event in
the development of breast cancers. Small, mammographically
detected breast cancers form a useful group for study of the
involvement of tumour-suppressor genes in tumour development
and earlier stages ofprogression. In this report, we examined LOH
at the more distal region, chromosome 6q25-q27, using four poly-
morphic microsatellite markers, in a group of 75 'early' lesions
comprising 59 mammographically detected invasive carcinomas
and 16 preinvasive lesions ofductal carcinoma in situ (DCIS).
The markers span a chromosomal region of approximately
15 Mb. Two of the markers (D6S186 and D6S193) were analysed
previously in well-established carcinomas (Orphanos et al, 1995).
The two other markers studied comprise repeats at or within
coding sequences that might be candidates for 'early' mutations in
breast cancer: a (TA)n repeat positioned 1 kb upstream of the
oestrogen receptor gene (ESR) (Del Senno et al, 1992) and a
(CAG)n repeat within the human TATA box-binding protein (TBP)
(Polymeropoulos et al, 1991). We have analysed the frequency of
LOH in the two groups of cases and correlated these data with
oestrogen receptor (ER) and progesterone receptor (PR) status and
other clinicopathological findings.
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Table 1 Clinicopathological features of 59 mammographically detected early
invasive breast carcinomas
Type Grade Number of Tumour size Number of
cases (mm) cases
Tub 6 <10 10
Lob/tub 1 10 14
IDC/ILC II 1 11 4
ILC II 1 12 5
IDC 17 (1) 13 3
IDC II 29 (2) 14 2
IDC III 4 15 21
Total 59 59
Tub, tubular carcinoma; Lob/tub, lobular and tubular carcinoma; IDC/ILC,
infiltrating ductal with infiltrating lobular carcinoma; ILC, infiltrating lobular
carcinoma; IDC, infiltrating ductal carcinoma. Numbers in brackets, node-
positive cases.
MATERIALS AND METHODS
Patients
A total of59 invasive breast carcinomas that were impalpable and
detected by mammography were studied. All were from the preva-
lent round of screening and were detected by the Leicestershire
Breast Screening Service. Cases of 15 mm or less in maximum
diameter were examined. All had either axillary node sampling or
axillary dissection. None of the tumours were from women with
either a strong family history ofbreast cancer or any known inher-
ited predisposition to the development of tumours. Some 56 cases
were node negative.
A total of 16 cases ofpure ductal carcinoma in situ (DCIS) were
studied. These comprised three low, three intermediate and ten
high nuclear grade cases. Ten of these were mammographically
detected and six were clinically presenting.
Tissues
All tissues were fixed in 4% formaldehyde in saline for 18-36 h.
After slicing, selected blocks were processed through graded
alcohols and xylene to paraffin wax. Following review of
haematoxylin and eosin-stained sections, representative blocks
were chosen for further study. Tissue from histologically normal
lymph node served as the source ofnormal DNA.
Histology
All carcinomas were reported according to the NHS Breast
Screening Programme National Coordinating Group for Breast
Screening Pathology Guidelines (1995). Infiltrating ductal carci-
nomas were graded using the modified Bloom and Richardson
system (Elston and Ellis, 1991). Cases of DCIS were graded as
low, intermediate or high nuclear grade. All histology was under-
taken by RA Walker. The clinicopathological features of the
invasive carcinomas are shown in Table 1.
Oestrogen receptor and progesterone receptor
immunohistochemistry
Avidin-biotin complex peroxidase immunohistochemistry was
carried out for the 59 early invasive carcinomas as described
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Figure 1 Loss of heterozygosity in early breast cancer. Genomic DNA
samples from paired normal lymph node (N) and microdissected tumour (T)
samples were compared by PCR amplification, electrophoresis on 6%
sequencing gels and autoradiography. (A) LOH at D6S193 in case 37:
(T1-T3) solid component of infiltrating ductal carcinoma. (B) LOH at D6S186
in case 21: (Ti and T2) solid component of infiltrating ductal carcinoma.
(C) LOH at D6S193 in case 102: (Ti and T2) solid component of infiltrating
ductal carcinoma. (D) LOH at D6S186 in DCIS case D5: (Ti and T2)
individual ducts. (E) LOH at ERTA in case 57: (T1) area of DCIS, (T2) tubular
component, (T3) tubular component
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Table 2 Pattern of loss of heterozygosity observed using four microsatellite markers from 59 early invasive breast carcinomas
Case no. Type Grade Loss of heterozygosity at markers H scores
ESR (q25.1) D6S186(q26) D6S193(q27) TBP (q27) ER PR
3 ILC II 0 0 NI 0 175 106
7 IDC 0 NI 0 0 182 49
13 Tub O O NI 0 142 94
15 IDC 0 NI NI 0 181 97
17 Tub 0 0 NI 0 195 3
19 IDC II 0 NI 0 0 162 168
21 IDC II 0 0 0 NI 151 92
23 IDC * * NI NA 175 31
29 Lob/tub * NI 0 NI 196 0
31 IDC MSI NI NI * 202 115
37 IDC II NI O 0 0 22 3
41 IDC II NI 0 0 0 192 170
49 IDC II NI 0 NI NI 215 46
57 IDC 0 NI 0 NT 173 192
59 IDC 0 0 * NI 196 19.2
70 IDC 0 NI NA NI 231 0
76 IDC * NI NA NI 219 0
78 IDC NI * 0 NT 202.5 85
80 Tub NI NI 0 NI 162 83
98 IDC II 0 * * NT 187.5 0
102 IDC 11 *0 0 NT 142 0
106 IDC II 0 NI 0 NT 195 33.5
108 IDC II * NI * NI 0 0
122 IDC II NI NI 0 NI 160 0
0, loss of heterozygosity; 0, heterozygosity; MSI, microsatellite instability; NI, not informative; NA, no amplification; NT, not tested, Tub, tubular carcinoma;
Lob/tub, lobular and tubular carcinoma; ILC, infiltrating lobular carcinoma; IDC, infiltrating ductal carcinoma.
Table 3 Pattern of loss of heterozygosity observed using three microsatellite
markers from 16 preinvasive lesions of DCIS
Case no. Grade Chromosome 6q markers
ESR D6S186 D6S193 TBP
(q25.1) (q26) (q27) (q27)
D2 (M) High NA 0 NI NT
D3 (M) Low 0 NI 0 NT
D4 (M) Low NI 0 0 NT
D5 (M) High * 0 0 NT
D8(M) Low NI NI 0 NT
D12 (C) High NI 0 * NT
D13 (C) High 0 NI 0 NT
D14 (C) High NI NI 0 NT
0, loss of heterozygosity; 0, heterozygosity; NI, not informative; NA, no
amplification; NT, not tested; (M), mammographically detected; (C), clinically
presenting.
previously (Rajakariar and Walker, 1995) with minor modifica-
tions. For antigen retrieval pretreatment, sections were exposed to
two cycles of microwaving for oestrogen receptor [mouse mono-
clonal IDS (Dako)] and progesterone receptor [mouse monoclonal
NCL-PgR (NovaCastra)].
DNA extraction and microdissection from paraffin
embedded sections
Formalin-fixed, paraffin-embedded tissue from breast tumour
samples and non-involved lymph nodes served as the source of
tumour and normal DNA respectively. For each tumour-normal
pair, DNA was extracted from 10-im paraffin-embedded sections
as described previously (Shaw et al, 1996).
Microdissection of tumour foci from invasive carcinomas and
areas of DCIS was carried out using a method based on that
described by Koreth et al (1995). In brief, serial 10-,um paraffin
sections were deparaffinized in xylene (2 x 5 min) and dehydrated
in 99% ethanol (2 x 2 min) and 95% ethanol (1 x 2 min), and rehy-
drated in water before staining. Tissues were stained in 0.5% eosin
solution for 20 s, washed in water and allowed to air dry. A serial
reference slide foreach tumour was stained with haematoxylin and
eosin, dehydrated and coverslipped. Tumour foci of interest from
the invasive carcinomas included tubular, solid, invasive lobular
components and preinvasive areas of ductal carcinoma in situ
(DCIS) within infiltrating ductal carcinomas. These areas were
visualized using the haematoxylin and eosin reference and
microdissected from corresponding eosin sections using a x 40
magnification microdissection microscope (American Optical
Corporation) using sterile, 20-jl drawn-out glass Pasteur pipettes.
Tumour foci (approximately 100 cells) were placed into 25 jil of
digestion buffer [100 mM Tris-HCl (pH 7.6), 1 mm EDTA (pH 8),
200 jg ml-' proteinase K] and incubated at 55°C for 3 h, then at
94°C for 10 min. Volumes (2 jl) of this mixture were used in the
PCR analysis.
PCR analysis at 6q25.1-27
A total of 75 'early' breast carcinomas were studied for LOH at
four polymorphic markers from chromosome 6q25.1-27: the
oestrogen receptor (ESR) at 6q25.1 (Del Senno et al, 1992),
D6S186 (6q26) and D6S193 (6q27) (Saito et al, 1992; Orphanos et
al, 1995) and the TATA box-binding protein (TBP) gene at 6q27
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(Polymeropoulos et al, 1991; Saito et al, 1994). PCR reaction
conditions were as follows: 45 mm Tris-HCl, pH 8.8, 11 mM
ammonium sulphate, 4.5 mm magnesium chloride, 200 gM dTTP,
dCTP and dGTP, 25 gM dATP (Pharmacia, UK), 0.3 gl [ax-
35S]deoxyadenosine-5'-triphosphate (600 Ci mmol-', 10 mCi ml-';
ICN Pharmaceuticals, UK), 113 gg ml-' bovine serum albumin
(Boehringher Mannheim), 6.7 mM f-mercaptoethanol, 4.4 gM
EDTA, pH 8.0, 10 pmol of forward and reverse primers, 2 ,ul of
microdissected DNA and 1 unit Taq DNA polymerase (Gibco
BRL, UK) in a total volume of 25 gl. Hot-start PCR was carried
out using the following cycles: 5 min denaturation at 94°C
followed by 30 (40 for microdissections) cycles of 1 min denatura-
tion at 94°C, 1 min annealing and 1 min extension at 72°C with a
final extension of 7 min at 72°C on a DNA Thermal Cycler
(Perkin Elmer Cetus, UK). Analysis of PCR products was as
described previously (Shaw et al, 1996).
Detection of LOH
Autoradiographs were scored independently by two individuals
(SC and JS) and the results compared. All examples of LOH were
confirmed by microdissection analysis to prepare multiple tumour
foci and then by repeating the PCR analysis where possible.
RESULTS
A total of 59 early invasive breast tumours and 16 preinvasive
lesions of DCIS were screened for LOH with four polymorphic
microsatellite markers, mapping to chromosome 6q25. I-q27.
LOH was considered to be present when the constitutive tissue
DNA was heterozygous (informative) for the locus under investi-
gation, and where there was complete or > 50% loss of one allele
in the corresponding tumour DNA as estimated by visual inspec-
tion. The complex heterogeneity ofthe disease and the presence of
non-tumour cells can mask LOH, therefore all analyses were
confirmed using DNA prepared by microdissection from different
histological tumour foci within the same tumour section (Figure
1). The use of microdissected tumour material produced almost
complete allelic loss (Figure 1), such that densitometric analysis of
the data was not considered necessary.
For example, Figure 1 B, C and D shows two invasive carci-
nomas and one case of DCIS that all exhibit complete LOH for
two separate microdissecvted foci at the markers studied. The
tumours analysed in Figure 1A and E show some evidence of
heterogeneity with variation between different microdissected
foci. For example Figure lE is an infiltrating ductal carcinoma
grade I that exhibits LOH at ERTA. Analysis of three distinct
microdissected foci shows an area of in situ carcinoma with LOH
(Tl), a tubular component with heterogeneity of LOH (T2) and a
second tubular component with complete LOH (T3). This discrep-
ancy could be attributable to the presence of contaminating non-
neoplastic stromal cells in the tubular component, even when it
was dissected away from normal tissue. Although microdissection
analysis revealed occasional heterogeneity of distinct structural
components, e.g. in situ, solid or tubular lesions within a tumour
section, with some foci showing clear LOH and others showing no
evidence of LOH, no clear correlation was seen between specific
structural components and LOH at any particular locus.
Table 2 and 3 summarize the observed patterns of LOH at
6q25.lI-q27 for the invasive and preinvasive study groups respec-
tively. LOH was seen for all types and grades of disease studied.
Altogether, 24 of 59 invasive carcinomas (48%) showed evidence
of LOH. Of these, 17 exhibited LOH only at a single locus (Table
2) and one tumour (case 31) also showed clear microsatellite insta-
bility at ESR. The situation was similar for the cases ofDCIS with
eight of 16 cases (50%) showing evidence of LOH and five of
these only exhibiting LOH at a single locus (Table 3). The
frequency of LOH at individual markers ranged from 23% to
40.6% for the early invasive cases and from 33.3% to 50% for the
DCIS group (Table 4). The highest- frequency of LOH was
observed at the ESR locus for the invasive carcinomas and at the
D6S186 locus for the cases of DCIS. LOH was observed in both
high- and low-grade DCIS. The cases of DCIS were not studied
for LOH at the TBP marker owing to the paucity of available
material for study.
In addition, the 59 early invasive carcinomas were studied for
oestrogen receptor and progesterone receptor status by immuno-
histochemistry (Table 2). In all, 53 (90%) were oestrogen receptor
positive and 27 (46%) were progesterone receptor positive.
Thirteen ofthe early invasive carcinomas showed LOH at the ESR
locus. Ofthese, 12 were ER positive (92%) and four were PR posi-
tive (31%) by immunohistochemistry (Table 2). Therefore, LOH
at ESR is not necessarily reflected in negative values for ER
and/or PR. There was no significant relationship between LOH at
ESR and either ER or PR status.
DISCUSSION
Using microdissection of distinct structural components from
within a tumour tissue section and PCR amplification of
microsatellite repeats, we have demonstrated loss ofheterozygosity
(LOH) at chromosome 6q25.1-27 in foci ofboth DCIS and 'early'
invasive carcinomas. Comparing the proportion of in situ lesions
with the proportion of invasive lesions exhibiting LOH at each
locus revealed similar frequencies. Moreover, there was a general
spread ofLOH detected for all types and grades ofdisease studied.
These data for the 'early' carcinomas suggest that the majority
of allele losses previously reported at these loci in symptomatic
Table 4 Summary of chromosome 6q LOH data in early invasive tumours and preinvasive cases of DCIS
Locus Chromosomal location No. of cases tested No. of informative cases (%) No. of cases with LOH (%)
Invasive DCIS Invasive DCIS Invasive DCIS
ESR 6q25.1 57 15 32 (56) 9 (60) 13 (40.6) 3 (33.3)
D6S186 6q26 54 16 23 (42.6) 8 (50) 7 (30.4) 4 (50)
D6S193 6q27 57 16 35 (61.4) 12 (75) 11 (31.4) 5 (41.7)
TBP 6q27 28 - 13 (46) - 3 (23) -
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invasive cancers (Orphanos et al, 1995; Iwase et al, 1995) can be
found in preinvasive carcinomas. This suggestion is supported by
evidence from a small number of the infiltrating ductal carcinomas
(e.g. Figure 1) in which it was possible to analyse an invasive and in
situ component from the same tumour section. In each case, LOH
was detected in both lesions. In combination, these data suggest
that loss of alleles on chromosome 6q is an early event in the
progression ofmalignancy in the breast.
Although the highest frequency of LOH was observed at the
ESR locus (40.6%) for the invasive carcinomas and at the D6S186
locus (50%) for the cases of DCIS, these differences may merely
reflect the different groups of cases studied and the difference in
sample size between the two groups. In addition, the slightly
higher frequency of LOH noted for the cases of DCIS may reflect
the fact that most were ofhigh nuclear grade, and therefore a more
aggressive disease type. It is interesting to note that LOH was
found for all three markers studied in both high- and low-grade
DCIS, suggesting the early involvement of loci on 6q in the devel-
opment of these lesions. In a study of chromosome 1, differences
were found between chromosomal regions for the different
subtypes of DCIS with no alteration at two regions in low-grade
DCIS (Munn et al, 1995).
The prevalent detection of LOH at a single locus rather than
multiple loci in both the 'early' invasive carcinomas and cases
of DCIS argues against random losses resulting from general
chromosomal instability and gross chromosomal alterations. Some
invasive carcinomas and cases ofDCIS showed LOH at more than
one locus. Since the markers studied map from 6q25-27, a
distance of several megabases, it is not possible to say whether
a contiguous region harbouring the relevant loci has been lost,
or whether there are distinct areas of LOH within this region of
chromosome 6q.
Knowledge of the ER status of a carcinoma is ofvalue in aiding
prediction ofhormone responsiveness and can provide some prog-
nostic information. Tumours lacking ER and PR generally grow
faster than those containing both ER and PR (McGuire and Clark,
1989). Overall, 46.1% of informative cases for the invasive carci-
nomas exhibited LOH at the oestrogen receptor locus (ESR), and
33% ofthe informative cases ofDCIS showed LOH at ESR. These
frequencies are higher than the 19% LOH at ESR observed by
Iwase et al (1995) and may reflect different groups of cases, or
might be due to the more informative analysis ofmaterial prepared
by microdissection in this study. The high incidence ofLOH at the
ESR locus in the invasive carcinomas was not reflected by loss of
ER as detected by immunohistochemistry. Indeed, the majority of
the group of early invasive lesions were ER positive. This would
be expected, since the group studied was predominantly well or
moderately differentiated. Evolving tumour cells may later acquire
new proliferative pathways as a consequence of multiple genetic
alterations, enabling the tumour cells to bypass oestrogen-
dependent proliferation (Liu et al, 1988).
Other studies have found no relationship between LOH on chro-
mosome 6q and ER status (Devilee et al, 1991; Iwase et al, 1995),
suggesting that allele loss may not play an important role in the
lack of ER function in breast cancer tissues. However, our results
have identified nine of 13 tumours exhibiting LOH at ESR that
were ER positive and PR negative. This might indicate inactiva-
tion of the remaining ESR allele leading to production of an inac-
tive but detectable ER protein, and hence loss of PR. These cases
are candidates for screening for either mutations or spliced vari-
ants of the oestrogen receptor gene. The identification of spliced
variants would seem most likely, since ER-positive/PR-negative
phenotype breast tumours were shown by Fuqua et al (1993) to
contain a variant ER (missing exon 7) that was unable to function
as a transcriptional inducer ofPR expression.
Only three invasive carcinomas showed evidence ofLOH at the
TBP locus (23%), at 6q27. This frequency ofLOH is only margin-
ally raised above expected levels for random background loss.
These data suggest that inactivation of this region of the chromo-
some is of lesser importance than of that harbouring the ESR,
D6S186 and D6S193 loci in these early lesions.
The mannose 6-phosphate/insulin-like growth factor 2 receptor
(M6P/IGFr) functions in the intracellular trafficking of lysosomal
enzymes, the degradation of IGF2, a mitogen often overproduced
in tumours (Kornfeld, 1992), and the activation of the potent
growth inhibitor, transforming growth factor f (Dennis and Rifkin,
1991). Some 70% ofhuman hepatocellular carcinomas show LOH
at this locus, which maps to chromosome 6q26-27 (Laureys et al,
1988), and 25% of these show point mutations in the remaining
allele (De Souza et al, 1995). Clearly, M6P/IGFr might be inacti-
vated in breast cancers also. Recently, Hankins et al (1996)
reported point mutations in two comedo-type (high-grade) DCIS
cases, suggesting that this is a candidate tumour-suppressor gene
in some breast cancers. Ourpreliminary analyses ofthis locus have
shown no evidence of LOH in the well to moderately differenti-
ated invasive carcinomas suggesting that inactivation of
M6P/IGFr is not common in these tumours (manuscript in prepara-
tion). In combination, these data suggest that inactivation of
M6P/IGFr may occur only within certain more aggressive
subgroups (poorly differentiated cases) of breast cancers. The
frequent LOH that we have detected at 6q25. 1-q27 might, there-
fore, be caused by inactivation of other tumour-suppressor genes
on chromosome 6q as well as M6P/IGFr.
In summary, we have detected frequent LOH at three polymor-
phic loci from chromosome 6q25. 1-27 in cases of both high- and
low-grade DCIS and all types and grades of early invasive carci-
nomas. In combination, these data confirm distal chromosome 6q
as a major site for genetic change in the early stages of develop-
ment of some sporadic breast cancers, and form the starting point
to identify the corresponding genes.
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